Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decline in Short Interest

Ainos, Inc. (NASDAQ:AIMD) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 143,300 shares, a decline of 40.0% from the October 15th total of 238,800 shares. Currently, 5.7% of the shares of the company are short sold. Based on an average daily trading volume, of 656,000 shares, the short-interest ratio is currently 0.2 days.

Ainos Stock Performance

Shares of Ainos stock opened at $0.49 on Thursday. The business has a 50-day moving average price of $0.51 and a 200 day moving average price of $0.71. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.33 and a current ratio of 1.37. Ainos has a twelve month low of $0.40 and a twelve month high of $4.29.

Ainos (NASDAQ:AIMD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter. Ainos had a negative return on equity of 75.16% and a negative net margin of 15,348.14%.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.